leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...201202203204205206207208209210211...235236»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
    Enrollment open, Trial initiation date, Trial primary completion date:  FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) -  Feb 21, 2016   
    P2,  N=25, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2016 | Trial primary completion date: Jul 2018 --> Feb 2018
  • ||||||||||  oxaliplatin / Generic mfg., irinotecan / Generic mfg.
    Enrollment closed, Enrollment change:  Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (clinicaltrials.gov) -  Feb 18, 2016   
    P2,  N=1, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2016 | Trial primary completion date: Jul 2018 --> Feb 2018 Recruiting --> Active, not recruiting | N=32 --> 1
  • ||||||||||  Trial primary completion date, Metastases:  Molecularly Tailored Therapy for Pancreas Cancer (clinicaltrials.gov) -  Feb 17, 2016   
    P2,  N=20, Active, not recruiting, 
    Trial primary completion date: Oct 2016 --> Jul 2017 Trial primary completion date: Dec 2015 --> Jun 2016
  • ||||||||||  telisotuzumab (h224G11) / AbbVie
    Trial primary completion date, Metastases:  Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Feb 17, 2016   
    P1,  N=124, Active, not recruiting, 
    Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Apr 2016
  • ||||||||||  NN1213 / Novo Nordisk
    Trial primary completion date:  A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Feb 12, 2016   
    P2,  N=100, Active, not recruiting, 
    Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  Enrollment change:  Mature B-Cell Lymphoma And Leukemia Study III (clinicaltrials.gov) -  Feb 12, 2016   
    P2/3,  N=122, Recruiting, 
    Trial primary completion date: Dec 2015 --> Dec 2016 N=60 --> 122
  • ||||||||||  Enrollment open, Trial initiation date, Trial primary completion date:  Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma (clinicaltrials.gov) -  Feb 12, 2016   
    P2,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Dec 2015 | Trial primary completion date: Jan 2017 --> Jan 2018
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Enrollment closed, Enrollment change, Combination therapy, Metastases:  Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Feb 11, 2016   
    P2,  N=181, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Dec 2015 | Trial primary completion date: Jan 2017 --> Jan 2018 Recruiting --> Active, not recruiting | N=240 --> 181
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment open, Combination therapy, Metastases:  FABLOx: Study of 5-fluorouracil (5-FU), Nab (clinicaltrials.gov) -  Feb 8, 2016   
    P1/2,  N=78, Recruiting, 
    N=40 --> 3 | Recruiting --> Terminated; Recruitment difficulties Not yet recruiting --> Recruiting
  • ||||||||||  EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
    Enrollment closed, Trial primary completion date, IO biomarker, Metastases:  Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) -  Feb 4, 2016   
    P1,  N=30, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016
  • ||||||||||  EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
    Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases:  NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) -  Feb 4, 2016   
    P1/2,  N=43, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016 Not yet recruiting --> Recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment closed, Metastases:  AXEPT: A Phase III Study of 2nd-line XELIRI  (clinicaltrials.gov) -  Feb 3, 2016   
    P3,  N=650, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
    New P1 trial, PD(L)-1 Biomarker, IO biomarker, Metastases:  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) -  Feb 2, 2016   
    P1,  N=208, Not yet recruiting, 
  • ||||||||||  futuximab/modotuximab (S95026) / Servier
    Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) -  Feb 1, 2016   
    P1/2,  N=50, Not yet recruiting, 
    Phase classification: P2/3 --> P3 | N=256 --> 175 | Trial primary completion date: May 2017 --> Sep 2017 Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2017 --> May 2018
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD), Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
    Phase classification:  Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I (clinicaltrials.gov) -  Feb 1, 2016   
    P1/2,  N=50, Recruiting, 
    Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2017 --> May 2018 Phase classification: P2 --> P1/2
  • ||||||||||  Trial primary completion date:  Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) -  Jan 30, 2016   
    P2,  N=40, Recruiting, 
    N=360 --> 44 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Dec 2015; Low or poor accrual Trial primary completion date: Oct 2015 --> Dec 2016
  • ||||||||||  Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
    Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Jan 25, 2016   
    P1,  N=21, Active, not recruiting, 
    Trial primary completion date: Apr 2015 --> Apr 2017 Recruiting --> Active, not recruiting | N=15 --> 21 | Trial primary completion date: Apr 2016 --> Jan 2016
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment change, Combination therapy:  FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) -  Jan 22, 2016   
    P1/2,  N=35, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jan 2018 --> Jan 2016 N=25 --> 35